Rituxan Articles
Stock Commentary - Tokyo
19 July 2001
Net income increases 28% at Genentech
12 July 2001
Roche's MabThera wins NICE appeal
3 July 2001
Roche's MabThera approved in Japan
21 June 2001
Stock Commentary - New York
7 June 2001
MabThera filed for aggressive NHL in EU
18 May 2001
FDA asks for more data on Zevalin
11 May 2001
Genentech wins dispute on cancer drug patents
10 May 2001
IDEC Pharma sees Rituxan sales leap 115% in 1st qtr 2001
24 April 2001
Stock Commentary - New York
19 April 2001
Dip in 1st-qtr pharma sales at Roche
11 April 2001
MabThera use extends into transplant setting
27 March 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Genentech net income rises 30% for 2000
23 January 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Rituxan combination ups survival in NHL; Zevalin update
6 December 2000
Rituxan combination ups survival in NHL
1 December 2000
IDEC files for Zevalin OK in USA
3 November 2000
GW wins over Roche in oncology drug lawsuit
2 November 2000
Rituxan efficacy in RA?
2 November 2000
Rituxan sales reach $115 million in third quarter, says IDEC
12 October 2000
Genentech sees 25% increase in product sales
12 October 2000
IDEC gets "completed review" letter for Rituxan sBLA
28 September 2000
Genentech sales up 15%, but loss incurred
20 July 2000
Stock Commentary New York
22 June 2000
IDEC grows pipeline with immunotherapies
18 April 2000
Rituxan approved in Canada
13 April 2000
Pharma sales drive Roche growth in Q1
13 April 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Stock Commentary New York
16 December 1999
Genentech and IDEC seek to broaden NHL indications for Rituxan
8 December 1999
Stock Commentary New York
18 November 1999
Stock Commentary New York
28 October 1999
Stock Commentary New York
21 October 1999
Roche reducing stake in Genentech
11 October 1999
Stock Commentary New York
16 September 1999
Coulter and SB suffer on Bexxar resubmission
31 August 1999
Stock Commentary New York
12 August 1999
Idec to hand Rituxan manufacturing to Genentech
24 June 1999
Coulter to file for Bexxar approval soon
24 June 1999
Stock Commentary New York
10 June 1999
IDEC Shares Soar On Rituxan News
3 June 1999
Extended Rituxan regimen boosts response
26 May 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
IDEC looking to hit acquisition trail
16 March 1999
SB postpones trial of arthritis antibody
24 December 1998
Stock Commentary New York
17 December 1998
Celltech Makes Solid Six-Month Progress
16 December 1998
Rituxan Monitoring Letter In USA
8 December 1998
Roche's Rituxan/MabThera Warning In European Union
1 December 1998
Latest Wave Of US 1st Quarter Results
29 October 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
Herceptin Heads Cancer Drugs Backed In USA
10 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
Rituxan Revenues Boost Genentech's 2nd Quarter
14 July 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
Better News For Roche As Xenical Sees First Launch
18 June 1998
Roche's MabThera Approved In The EU
4 June 1998
Coulter Unveils Promising Bexxar Data
21 May 1998
CellTech Makes Solid Six-Month Progress
19 May 1998
Cancer: New Therapeutics, And Quality Of Life
30 April 1998
US Biotech To Break Even By Start Of Millennium?
29 April 1998
US Quarterly Financial Results Round-Up
23 April 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Coulter Pharmaceutical On Road To Success
19 March 1998
Stock Commentary New York
5 March 1998
IDEC Begins Ph III Registration Trial
4 March 1998
More US Year-End 1997 Corporate Results
24 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Roche Sales Grew 18% In 1997; Pharma Up 15%
16 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Rituxan Now Shipping In The USA
18 December 1997
Celltech Reflects On Pipeline After Mixed Fortunes In '97
16 December 1997
First Approval And Launch For IDEC's Rituxan
3 December 1997
Sharp Rise In Revenues For IDEC
27 November 1997
3rd Qtr Sales And Earnings Take A Dip At Genentech
16 October 1997
FDA Needs More Data On IDEC's Rituxan
4 September 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
